Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$2.8 million.

  • Ocular Therapeutix's Cash from Investing Activities fell 130544.55% to -$2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$11.9 million, marking a year-over-year decrease of 82236.02%. This contributed to the annual value of -$11.9 million for FY2025, which is 82236.02% down from last year.
  • Per Ocular Therapeutix's latest filing, its Cash from Investing Activities stood at -$2.8 million for Q4 2025, which was down 130544.55% from -$6.0 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Cash from Investing Activities high stood at -$89000.0 for Q3 2024, and its period low was -$6.0 million during Q3 2025.
  • Its 5-year average for Cash from Investing Activities is -$1.2 million, with a median of -$563000.0 in 2021.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 9245.34% in 2024, then plummeted by 663370.79% in 2025.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Cash from Investing Activities stood at -$631000.0 in 2021, then tumbled by 240.73% to -$2.2 million in 2022, then soared by 78.65% to -$459000.0 in 2023, then surged by 55.99% to -$202000.0 in 2024, then tumbled by 1305.45% to -$2.8 million in 2025.
  • Its Cash from Investing Activities was -$2.8 million in Q4 2025, compared to -$6.0 million in Q3 2025 and -$1.1 million in Q2 2025.